共 16 条
[1]
Treatment of tuberculosis:guidelines. World Health Organization. . 2010
[2]
WHO treatment guidelines for drug-resistant tuberculosis (2016 update). World Health Organization. . 2016
[4]
肺结核诊断和治疗指南[J]. 国实用乡村医生杂志. 2013 (02)
[5]
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy[J] . Junichi Azuma,Masako Ohno,Ryuji Kubota,Soichiro Yokota,Takayuki Nagai,Kazunari Tsuyuguchi,Yasuhisa Okuda,Tetsuya Takashima,Sayaka Kamimura,Yasushi Fujio,Ichiro Kawase.  European Journal of Clinical Pharmacology . 2013 (5)
[7]
An official ATS statement: hepatotoxicity of antituberculosis therapy. Saukkonen Jussi J,Cohn David L,Jasmer Robert M,Schenker Steven,Jereb John A,Nolan Charles M,Peloquin Charles A,Gordin Fred M,Nunes David,Strader Dorothy B,Bernardo John,Venkataramanan Raman,Sterling Timothy R. American Journal of Respiratory and Critical Care Medicine . 2006
[8]
Therapeutic drug monitoring in the treatment of tuberculosis. CA Peloquin. Drugs . 2002
[9]
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA. Scott K. Heysell,Jane L. Moore,Suzanne J. Keller. Emerging Infections . 2010
[10]
NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. P-Y. Wang,S-Y. Xie,Q. Hao. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE . 2012